High CD8/CD33 ratio in peritoneal metastatic lesions is associated with favorable prognosis in gastric cancer

Takahisa Yamaguchi | Jun Kinoshita | Hiroto Saito | Mari Shimada | Siro Terai | Hideki Moriyama | Koichi Okamoto | Isamu Makino | Keishi Nakamura | Hidehiro Tajima | Itsu Ninomiya | Sachio Fushida

Department of Gastroenterological Surgery, Division of Cancer Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan

Correspondence
Sachio Fushida, Department of Gastroenterological Surgery, Division of Cancer Medicine, Kanazawa University Graduate School of Medical Science 13-1 Takara-machi, Kanazawa 920-8641, Japan. Email: fushida@staff.kanazawa-u.ac.jp

Abstract

Background: Tumor-infiltrating lymphocytes (TILs) and other immune cells have been reported as a prognostic factor in several tumors, including gastric cancer, and they play an important role in antitumor effect at the primary site. There were few reports on the immune status in peritoneal metastatic lesions for gastric cancer.

Aims: The aims of this study were to assess the prognostic significance of TILs (CD4, CD8, CD19, regulatory T cells [Tregs]), and myeloid-derived suppressor cells (MDSCs) in peritoneal metastatic lesions.

Methods: We retrospectively investigated 60 patients for gastric cancer with peritoneal metastasis who were treated between 2009 and 2016 in our institute. Immunohistochemistry for CD4, CD8, CD19, FOXP3, and CD33 was performed in the peritoneal metastatic lesions. The absolute numbers of immune cells and ratios were evaluated, and the relationship between immune-related marker and overall survival (OS) was investigated.

Results: A high infiltration of CD8+ lymphocytes or high CD8/CD33 ratio was a better prognosis for OS in univariate analysis using all immunologic variables (P = .012, P = .001). In multivariate analysis for clinical and immunologic variables, high CD8/CD33 ratio was identified as an independent prognostic factor for OS (Hazard ratio: 0.291, 95% confidence interval: 0.126-0.670, P = .004).

Conclusion: High CD8/CD33 ratio and high infiltration of CD8+ lymphocytes in peritoneal metastatic lesions were favorable prognoses for gastric cancer patients with peritoneal metastasis. It is necessary to modify the immune microenvironment result to increase the level of CD8+ lymphocytes in the peritoneal metastatic lesions.

KEYWORDS
CD8+ lymphocytes, gastric cancer, MDSCs, peritoneal metastasis, TILs

Abbreviations: CTLs, cytotoxic T lymphocytes; MDSCs, myeloid-derived suppressor cells; OS, overall survivals; TAMs, tumor-associated macrophages; TGF-β, transforming growth factor-β; TILs, Tumor-infiltrating lymphocytes; Tregs, regulatory T cells; VEGF, vascular endothelial growth factor.
BACKGROUND

Globally, gastric cancer is one of the most life-threatening diseases in the world, and a major cause of cancer-related deaths. Peritoneal metastasis is an incurable disease that occurs frequently in recurrent gastric cancer and associates with poor prognosis. Importantly, molecular mechanisms of peritoneal metastasis are poorly understood. Although various treatments have been developed for peritoneal metastasis, including systemic chemotherapy, intraperitoneal chemotherapy, sufficiently satisfactory outcomes have yet to be achieved; this indicates the need for novel treatment strategies, in addition to conventional surgery and chemotherapy.

It is thought that the progression and suppression of tumor depend on various cell-cell interactions in local and metastatic lesions in the tumor microenvironment. Several studies have attempted to investigate the relationship between tumor-infiltrating lymphocytes (TILs) and prognosis in several cancers, suggesting that TILs accumulation was associated with better prognosis. CD8 is a surface antigen expressed in cytotoxic T lymphocytes (CTLs) that recognize specific antigen and eliminate the foreign objects. Several studies have reported that high infiltration of CD8\(^+\) lymphocytes was associated with better overall survival (OS) and disease-free survival (DFS) in gastric cancer. Furthermore, CD4\(^+\) helper T cells play an important role in adaptive immune system by releasing cytokines. Higher infiltration of CD4\(^+\) lymphocytes is also related to favorable prognosis in gastric cancer. Furthermore, MDSCs have been shown to contribute to cancer evasion by suppressing the T lymphocytes and natural killer cells in tumor microenvironment. MDSCs commonly express the cell surface marker CD33 and CD11b, and CD33 positive cells in advanced gastric cancer correlated with worse prognosis.

Though many studies have been progressing in the primary lesions for immune microenvironment, there were few reports on the immune status in metastatic lesions, including peritoneal metastasis. We have previously reported that tumor-associated macrophages (TAMs) and mast cells contributed to the tumor progression during peritoneal metastasis. However, the role of lymphocytes in peritoneal metastasis is not well understood. It is important to evaluate the tumor immune microenvironment to develop new treatment strategies. In this study, we investigated the expression of immunocompetent cells and the relationship between cell density and prognosis in gastric cancer with peritoneal metastasis.

MATERIALS AND METHODS

2.1 Patients and specimens

Sixty patients for gastric cancer with peritoneal metastasis who were treated in our institute in the period between 2009 and 2016 were investigated. Prior to chemotherapy, the specimens from peritoneal metastases were collected either during surgery or staging laparoscopy. Age, sex, histologic type (according to Lauren classification), TNM stage (according to TNM classification), and European Cooperative Oncology Group (ECOG) performance status were evaluated by reviewing medical records. WHO Classification of Tumours, 5th edition was used for classification of cancer related factors. Peritoneal metastasis was categorized into three classifications (P1a-P1c) according to the 15th edition of the General Rules for Gastric Cancer Study of the Japanese Research Society for Gastric Cancer. The ascites level was classified into four groups (none, mild, moderate, and severe) using computed tomography as we previously reported. Patients received the chemotherapy of physician’s choice including taxane-based intraperitoneal chemotherapy. Immune checkpoint inhibitor was not used in all cases. Among the patients who were judged as resectable, gastrectomy was performed 4 to 8 weeks after their last day of chemotherapy.

| Table 1: Clinical and pathological data of 60 patients with gastric cancer with peritoneal metastasis |
|---------------------------------------------------------------|
| Characteristics                                              | (n = 60) |
| Age, years; median (range)                                    | 63 (28-83) |
| Gender                                                       |          |
| Male                                                         | 25       |
| female                                                       | 35       |
| Initial or Recurrence                                         |          |
| Initial                                                      | 48       |
| Recurrence                                                   | 12       |
| gastrectomy                                                  |          |
| –                                                            | 21       |
| +                                                            | 39       |
| ECOG performance status                                      |          |
| ≥0.1                                                         | 56       |
| 2                                                            | 4        |
| Borrman macroscopic type                                     |          |
| 1                                                            | 1        |
| 2                                                            | 3        |
| 3                                                            | 25       |
| 4                                                            | 26       |
| 5                                                            | 5        |
| Histology (Lauren classification)                            |          |
| Intestinal                                                   | 12       |
| diffuse                                                      | 48       |
| P status                                                     |          |
| P1a                                                          | 8        |
| P1b                                                          | 4        |
| P1c                                                          | 48       |
| Ascites                                                      |          |
| None                                                         | 23       |
| Mild                                                         | 17       |
| Moderate                                                     | 7        |
| Severe                                                       | 13       |
| Other distant metastasis                                     |          |
| –                                                            | 50       |
| +                                                            | 10       |

Note: P1a, greater omentum, lesser omentum anterior lobe of the transverse colonic membrane, or membrane of the pancreatic surface or spleen. P1b, a few scattered metastases to upper abdominal peritoneum. P1c, many metastases to the middle or lower peritoneum. Abbreviation: ECOG, European Cooperative Oncology Group.
2.2 | Immunohistochemistry

The specimens were dewaxed in xylene and rehydrated through graded ethanol for immunohistochemistry. Endogenous peroxidase activity was blocked by incubating in 3% H2O2 in methanol for 20 minutes at room temperature. Antigen retrieval was done using microwaving sections in citrate buffer at 95°C for 10 minutes. Subsequently, the sections were incubated for 2 hours at room temperature with primary antibody, anti-CD4 antibody (1:100, anti-CD4 mouse monoclonal, 4B12; Nichirei, Tokyo, Japan), anti-CD8 antibody (1:200, anti-CD8 rabbit polyclonal, ab4055; Abcam, Tokyo, Japan), anti-FOXP3 antibody (1:50, anti-FOXP3 mouse monoclonal, 236A/E7; Abcam), anti-CD33 antibody (1:100, anti-CD33 mouse monoclonal antibody, NCL-L-CD33; Leica Biosystems, NewCastle upon Tyne, UK), and anti-CD19 antibody (1:250, anti-CD19 rabbit monoclonal, EPR5906; Abcam, Tokyo, Japan). Secondary antibody was subsequently performed for 1 hour, and then the sections were developed in DAB solution.

2.3 | Evaluation of immunostaining

To evaluate the expression of immune-related markers in the specimens, five non-overlapping intratumoral fields were counted under high power fields. All slides were counted by two researchers (TY and JK). The mean numbers of positive cells in five fields were calculated in each antibody. The median number was used to divide the patients into two groups (low or high).

2.4 | Statistical analysis

We investigated the differences among the data sets using Fisher’s exact test using the computer software package SPSS version 25 (SPSS, Chicago, IL, USA). Survival curves were created using the Kaplan-Meier method and the log-rank test. OS was calculated from the date the diagnosis of peritoneal metastasis was established to death from any cause or the latest follow-up. The influence of each factor on patients’ survival was evaluated using Cox regression analysis. Multivariate analysis of survival distributions was performed using Cox proportional hazards regression models. *P* values < .05 were considered a statistically significant difference.

3 | RESULTS

3.1 | Patient clinicopathological characteristics

The characteristics of 60 patients are shown in Table 1. The median age of the patients was 63 years (28-83 years). Twenty-five patients were male (41.7%) and 48 (80.0%) had initial treatment. Thirty-nine

| TABLE 2 | Relationship between patient characteristics and overall survival |
|----------|------------------|----------------|-----------------|----------------|
| Variable                          | OR    | 95%CI     | Number of patients | *P* value |
| Age, years                      |       |           |                  |           |
| ≥70                              | 1.188 | 0.648-2.108| 16               | .313      |
| <70                              |       |           | 44               |           |
| Gender                          |       |           |                  |           |
| Male                             | 0.97  | 0.322-2.920| 26               | .956      |
| Female                          |       |           | 34               |           |
| Initial or Recurrence            |       |           |                  |           |
| Initial                          | 1.088 | 0.502-2.359| 48               | .831      |
| Recurrence                       |       |           | 12               |           |
| Gastrectomy                     |       |           |                  |           |
| –                                | 0.48  | 0.243-0.952| 21               | .036      |
| +                                |       |           | 39               |           |
| ECOG performance status         |       |           |                  |           |
| 0,1                              | 2.885 | 0.378-12.457| 56              | .309      |
| ≥2                              |       |           | 4                |           |
| Borrman type                    |       |           |                  |           |
| Type4                            | 0.982 | 0.538-1.791| 27               | .952      |
| Not                              |       |           | 33               |           |
| Histology (Lauren classification)|       |           |                  |           |
| Intestinal                      | 0.743 | 0.379-1.456| 12               | .385      |
| Diffuse                         |       |           | 48               |           |
| P status                        |       |           |                  |           |
| 1a,1b                           | 2.044 | 0.969-4.312| 13               | .056      |
| 1c                              |       |           | 47               |           |
| Ascites                         |       |           |                  |           |
| None-Moderate                   | 2.217 | 1.101-4.467| 46               | .022      |
| Severe                          |       |           | 14               |           |
| Other distant metastasis        |       |           |                  |           |
| –                                | 3.023 | 1.351-6.764| 9                | .005      |
| +                                |       |           | 51               |           |

Abbreviation: ECOG, European Cooperative Oncology Group.
patients had a history of gastrectomy and 21 had not undergone gastrectomy. Four patients (6.7%) were performance status (PS) ≥2, and 56 (93.3%) were PS of either 0 or 1. P status was P1a in 8 (13.3%), P1b in 4 (6.7%), and P1c in 48 (80.0%) patients. The ascites levels were as follows: 23 (38.3%) were none, 17 (28.3%) were mild, 7 (11.6%) were moderate, and 13 (21.7%) patients were severe.

3.2 | Relationship between clinical variables and OS

In univariate analysis of clinical variables, age, gender, initial or recurrence, ECOG performance status, Borrmann type, and pathology P status were not associated with OS (Table 2). On the other hand, OS was
significantly lower in patients with gastrectomy (−), severe ascites, and presence of distant metastases in addition to peritoneal metastasis.

### 3.3 Evaluation of immune-related cells in peritoneal metastasis

We investigated the five immunologic parameters (CD4 as helper T cells, CD8 as cytotoxic T cells, CD19 as B cells, FOXP3 as regulatory T cells [Tregs], and CD33 as myeloid-derived suppressor cells [MDSCs]). CD4, CD8, CD19, and CD33-positive cells showed cell membrane staining, whereas FOXP3-positive cells exhibited nuclear staining (Figure 1A-J).

The median number of cells positive for CD4, CD8, CD19, FOXP3, and CD33 were 6.1, 9.3, 3.6, 3.9, and 10.4. Based on the median numbers, all patients were divided into low or high density groups in each antibody, and then we performed the Kaplan-Meier test, followed by univariate and multivariate analyses.

### 3.4 Survival according to immunological parameters

As shown in Table 3, univariate analysis indicated the CD8 high-density groups were associated with better prognosis (P = .012; hazard ratio [HR]: 0.457, 95% confidence interval [CI]: 0.245-0.855). Median survival time (MST) in CD8 low density groups was 12.2 months, while that in CD8 high density groups was 28.5 months. In contrast, the densities of CD4, FOXP3, CD19, and CD33 cells were not associated with OS. For further validation of our results, combined ratio was also calculated. The subgroup of patients with high CD8/CD33 ratio had significantly improved OS (P = .001; HR: 0.275, 95%CI: 0.140-0.542). MST in low CD8/CD33 ratio groups was 11.0 months, while that in high CD8/CD33 ratio groups was 28.7 months. On the other hand, CD8/CD4, FOXP3/CD4, CD8/FOXP3, and CD4/CD33 ratios were not associated with OS. Figure 2A,B shows the Kaplan-Meier curves in 60 patients according to CD8 expression and CD8/CD33 ratio.

### 3.5 Multivariate analysis

Clinicopathological features and immunohistopathologic variables showing P ≤ .1 by univariate analysis were adopted as covariates when multivariate Cox proportional hazards analysis was performed (Table 4). Because there was an interaction between CD8 expression and CD8/CD33 ratio, multivariate analysis with Cox proportional hazards model was performed separately.

High CD8/CD33 ratio was an independent prognostic factor in the multivariate analysis for OS (P = .004; HR: 0.291, 95%CI: 0.126-0.670), but the high infiltration of CD8+ lymphocytes did not significantly differ in multivariate analysis (P = .115).

---

**Table 3:** Relationship between immunological parameters and overall survival

| Variable      | Median | Number of patients | HR   | 95%CI          | P value |
|---------------|--------|--------------------|------|----------------|---------|
| CD4           | 6.1    | Low                | 34   | 0.575          | 0.296-1.118 | .099    |
|               |        | High               | 26   |                |         |
| CD8           | 9.3    | Low                | 32   | 0.457          | 0.245-0.855 | .012    |
|               |        | High               | 28   |                |         |
| CD19          | 3.6    | Low                | 41   | 0.974          | 0.490-1.937 | .941    |
|               |        | High               | 19   |                |         |
| FOXP3         | 3.9    | Low                | 35   | 0.993          | 0.539-1.829 | .981    |
|               |        | High               | 25   |                |         |
| CD33          | 10.4   | Low                | 31   | 1.461          | 0.784-2.723 | .23     |
|               |        | High               | 29   |                |         |
| CD8/CD4       | 1.13   | Low                | 29   | 1.027          | 0.552-1.909 | .933    |
|               |        | High               | 31   |                |         |
| FOXP3/CD4     | 0.41   | Low                | 30   | 1.526          | 0.803-2.900 | .194    |
|               |        | High               | 30   |                |         |
| CD8/FOXP3     | 2.47   | Low                | 33   | 0.547          | 0.289-1.032 | .059    |
|               |        | High               | 27   |                |         |
| CD8/CD33      | 0.92   | Low                | 32   | 0.275          | 0.140-0.542 | .001    |
|               |        | High               | 28   |                |         |
| CD4/CD33      | 0.57   | Low                | 30   | 0.562          | 0.289-1.092 | .085    |
|               |        | High               | 30   |                |         |

Abbreviations: CI, confidence interval; FOXP3, forkhead box P3; HR, hazard ratio.
DISCUSSION

The abdominal cavity is thought to be a special environment where various cells are present and involved in tumor progression and suppression. Yet immune function in peritoneal cavity has not been sufficiently identified. In this study, we demonstrated that high infiltration of CD8+ lymphocytes and high CD8/CD33 ratio in peritoneal metastatic lesions were favorable prognostic factors. As far as we know, this is the first report showing the relationship between TILs and OS for gastric cancer with peritoneal metastasis. We have previously reported that the number of CD8+ lymphocytes was significantly lower in peritoneal metastasis site than in primary site.18 On the other hand, the present study indicated that the prognosis was better in patients with high CD8/CD33 ratio than that in those with low CD8/CD33 ratio (P = .001, log-rank).

Decreased infiltration of CTLs is thought to be reflected by the immunosuppressive microenvironment, resulting in difficulties to treat patients with peritoneal metastasis. The presence of CTLs in the tumor microenvironment induces the host immune response to tumor antigens, and inhibits tumor progression.20 Our results showed that high densities of TILs related to adaptive immunity contributed to chemosensitivity and favorable prognosis.

The reason for the different rate in CD8+ lymphocytes infiltration in peritoneal metastasis is unknown. Previously, we have established a peritoneal tumor model by co-inoculating the mouse gastric cancer cell line YTN16 and the mouse myofibroblast cell line YAMAGUCHI ET AL.

TABLE 4 Multivariate analysis of factors associated with prognosis in gastric cancer with peritoneal metastasis

| Variable                     | No. of patients | HR   | 95%CI          | P value |
|------------------------------|-----------------|------|----------------|---------|
| **Multivariate analysis with the density of CD8+ TILs** |                 |      |                |         |
| Gastrectomy                  | −               | 21   | 0.244-1.392    | .244    |
|                               | +               | 39   |                |         |
| P status                     | 1a,1b           | 13   | 1.517-3.604    | .345    |
|                               | 1c              | 47   |                |         |
| Ascites                      | None            | 46   | 1.327-3.163    | .523    |
|                               | Moderate        |        |                |         |
|                               | Severe          | 14   |                |         |
| Other distant metastasis     | −               | 9    | 2.438-6.017    | .053    |
|                               | +               | 51   |                |         |
| CD4                          | Low             | 34   | 0.772-1.611    | .491    |
|                               | High            | 26   |                |         |
| CD8                          | Low             | 32   | 0.564-1.123    | .103    |
|                               | High            | 28   |                |         |
| **Multivariate analysis with the CD8/CD33 ratio** |                 |      |                |         |
| Gastrectomy                  | −               | 39   | 0.558-1.280    | .169    |
|                               | +               | 21   |                |         |
| P status                     | 1a,1b           | 13   | 1.762-4.444    | .23     |
|                               | 1c              | 47   |                |         |
| Ascites                      | None            | 46   | 0.796-1.994    | .627    |
|                               | Moderate        |        |                |         |
|                               | Severe          | 14   |                |         |
| Other distant metastasis     | −               | 9    | 2.083-5.171    | .114    |
|                               | +               | 51   |                |         |
| CD4                          | Low             | 34   | 0.766-1.611    | .482    |
|                               | High            | 26   |                |         |
| CD8/CD33                     | Low             | 32   | 0.291-0.670    | .004    |
|                               | High            | 28   |                |         |

Abbreviations: CI, confidence interval; HR, hazard ratio; TILs, tumor-infiltrating lymphocytes.
CD4+ lymphocytes in gastric cancer mechanisms such as antigen presentation, T cell activation, and effector function. Li et al. reported that CD4+ lymphocytes include the Tregs or IL-17 secreting Th17 cells. IL-17 cytokines or chemokines such as vascular endothelial growth factor (VEGF) and transforming growth factor-β (TGF-β), which act as immunosuppressors in the tumor microenvironment. VEGF presence results in the decrease in CD8+ lymphocyte's proliferation and infiltration ability into tumor site. Furthermore, TGF-β inhibits the proliferation of CD8+ lymphocytes, and suppresses the ability of cytotoxicity. Indeed, increased concentration of both VEGF and TGF-β have been reported in peritoneal metastasis, thus CTL suppression occurred more strongly.

In this study, CD4+ TILs in metastatic lesions were not associated with OS. Helper T cells promote antitumor immunity by numerous mechanisms such as antigen presentation, T cell activation, and effector function. Li et al. reported that CD4+ lymphocytes in gastric cancer were not significantly associated with survival outcomes, which were similar to our results. Meanwhile, Liu et al. investigated that the high density of CD4+ lymphocytes resulted in improved survival. The relationship between CD4+ TILs in tumor site and prognosis was controversial. CD4+ lymphocytes include the Tregs or IL-17 secreting Th17 cells. IL-17 promotes tumor angiogenesis, proliferation, and invasion. Furthermore, Tregs are generally considered to be immunosuppressive cells. Therefore, the roles of CD4+ TILs are unclear and further investigation is needed for gastric cancer with peritoneal metastasis.

Several investigations demonstrated the importance of MDSCs in tumor-associated immune suppression. In this study, only high CD8/CD33 ratio was associated with favorable OS in multivariate analysis. CD8/CD33 ratio implies the infiltrate composed of many CD8+ lymphocytes with low numbers of immunosuppressive CD33+ MDSCs, and hence a better situation to fight the tumor growth. We have previously reported that CD33+ MDSCs were recruited to peritoneal metastatic lesions via platelet aggregation, which contributed to tumor progression. It is considered that the accuracy of a prognostic factor was further improved in combination with CD8.

This study had several limitations including the retrospective study design and the use of a small sample size of patients obtained from a single center. It is relatively difficult to obtain a lot of specimens from the corresponding author on reasonable request.

**REFERENCES**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7-30.
3. Yonemura Y, Prabhu A, Sako S, et al. Long term survival after cytoreductive surgery combined with perioperative chemotherapy in gastric cancer patients with peritoneal metastasis. Cancers (Basel). 2020;1:12.
4. Fushida S, Kinoshita J, Oyama K, et al. Multidisciplinary therapy for scirrhouus gastric cancer: a retrospective analysis and proposal of new treatment strategy. Cancer Manag Res. 2018;10:3833-3839.
5. Fushida S, Kinoshita J, Kaji M, et al. Phase I/II study of intraperitoneal doce taxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2013;71(5):1265-1272.
6. Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58:3491-3494.
7. Nakano O, Sato M, Naito Y, et al. Proliferative activity of intratumoral CD8+ T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer. 2001;61:5132-5136.
8. Lee HE, Chae SW, Lee YJ, et al. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer. 2008;99:1704-1711.
9. Dong J, Li J, Liu SM, et al. CD33+/p-STAT1+ double-positive cell as a prognostic factor for stage IIIa gastric cancer. Med Oncol. 2013;30:442.

**CONCLUSION**

High CD8/CD33 ratio and high infiltration of CD8+ lymphocytes into peritoneal metastatic lesions were associated with favorable prognosis in gastric cancer patients with peritoneal metastasis. CTLs play an important role in antitumor effect for peritoneal metastasis, although immunological ignorance often occurs in peritoneal cavity. We have to develop the treatment strategy for induction of CTLs infiltration.
10. Ohno S, Tachibana M, Fujii T, Ueda S, Kubota H, Nagasue N. Role of stromal collagen in immunomodulation and prognosis of advanced gastric carcinoma. *Int J Cancer*. 2002;97:770-774.

11. Kim HJ, Cantor H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. *Cancer Immunol Res*. 2014;2(2):91-98.

12. Kim H, Kim H, Cho HW, et al. The ratio of intra-tumoral regulatory T cells (Foxp3+)/Helper T cells (CD4+) is a prognostic factor and associated with recurrence pattern in gastric cardia cancer. *J Surg Oncol*. 2011;104(7):728-733.

13. Soeno T, Kato H, Ishii S, et al. CD33+ immature myeloid cells critically predict recurrence in advanced gastric cancer. 2020;245:552-563.

14. Yamaguchi T, Fushida S, Yamamoto Y, et al. Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination. *Gastric Cancer*. 2016;19(4):1052-1065.

15. Gunjigake K, Kinoshita J, Yamaguchi T, et al. Interleukin-17A derived from mast cells contributes to fibrosis in gastric cancer with peritoneal dissemination. *Gastric Cancer*. 2020;24:31-44. https://doi.org/10.1007/s10120-020-01092-2.

16. WHO Classification of Tumours Editorial Board. *WHO Classification of Tumours*. Vol 1. 5th ed. Geneva: World Health Organization; 2019: 54-64.

17. Fushida S, Oyama K, Kinoshita J, et al. VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody. *Onco Targets Ther*. 2013;16(6):1445-1451.

18. Fujimori D, Kinoshita J, Yamaguchi T, et al. Established fibrous peritoneal metastasis in an immunocompetent mouse model similar to clinical immune microenvironment of gastric cancer. *BMC Cancer*. 2020;20(1):11014.

19. Kitayama J, Ishigami H, Yamaguchi H, et al. Treatment of patients with peritoneal metastases from gastric cancer. *Ann Gastroenterol Surg*. 2018;2(2):116-123.

20. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunotherapy. *Annu Rev Immunol*. 2004;22:329-360.

21. Mulligan JK, Day TA, Gillespie MB, Rosenzweig SA, Young MR. Secrecion of vascular endothelial growth factor by oral squamous cell carcinoma cells skewhs endothelial cells to suppress T-cell functions. *Hum Immunol*. 2009;70(6):375-382.

22. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. *Cancer Res*. 2010;70(15):6171-6180.

23. Thomas DA, Massague J. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. *Cancer Cell*. 2005;8(5):369-380.

24. Na D, Lv ZD, Liu FN, et al. Transforming growth factor beta1 produced in autocrine/paracrine manner affects the morphology and function of mesothelial cells and promotes peritoneal carcinomatosis. *Int J Mol Med*. 2010;26(3):325-332.

25. Li K, Zhu Z, Luo J, et al. Impact of chemokine receptor CXCR3 on tumor-infiltrating lymphocyte recruitment associated with favorable prognosis in advanced gastric cancer. *Int J Clin Exp Pathol*. 2015;8(11):14725-14732.

26. Liu K, Yang K, Wu B, et al. Tumor infiltrating immune cells are associated with prognosis of gastric cancer. *Medicine (Baltimore)*. 2015;94:e1631.

27. Xiao Z, Xing Z, Yingjie S, et al. Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a meta-analysis. *OncoTarget*. 2017;22(34):57386-57398.

28. Fossiez F, Djoussou O, Chomarat P, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. *J Exp Med*. 1996;183:2593-2603.

29. Lv Q, Wu K, Liu F, Wu W, Chen Y, Zhang W. Interleukin-17A and heparanase promote angiogenesis and cell proliferation and invasion in cervical cancer. *Int J Oncol*. 2018;53(4):1809-1817.

30. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. *J Clin Oncol*. 2007;25:2586-2593.

31. Perrone G, Ruffini PA, Catalano V, et al. Intratumoral FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. *Eur J Cancer*. 2008;44(13):1875-1882.

32. Zhou S, Shen Z, Wang Y, et al. CCRT expression and intratumoral FOXP3+ regulatory T cells are correlated with overall survival and lymph node metastasis in gastric cancer. *PloS One*. 2013;8:e74430.

33. Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. *Cancer Immunol Immunother*. 2006;55(3):237-245.

34. Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. *Clin Cancer Res*. 2007;13(18 Pt 1):5243-5248.

35. Yamaguchi T, Fushida S, Kinoshita J, et al. Extravasated platelet aggregation contributes to tumor progression via the accumulation of myeloid-derived suppressor cells in gastric cancer with peritoneal metastasis. *Oncol Lett*. 2020;20(2):1879-1887.

How to cite this article: Yamaguchi T, Kinoshita J, Saito H, et al. High CD8/CD33 ratio in peritoneal metastatic lesions is associated with favorable prognosis in gastric cancer. *Cancer Reports*. 2021;e1389. https://doi.org/10.1002/cnr2.1389